AzTrials
AzTrials

Multiple Myeloma in RelapsePhase 1NCT04813653

Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

A Phase 1 study testing cyclosporine in combination with carfilzomib and dexamethasone in people with Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This phase 1, open-label, single-arm, prospective, single center study will evaluate the safety, tolerability and efficacy of cyclosporine in combination with carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma (RRMM). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
cyclosporine in combination with carfilzomib and dexamethasone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
3 participants
Where
1 siteIsrael
Study dates
18 Apr 2021to 5 Mar 2025
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients must meet all of the following inclusion criteria:
  • Male or female patients, 18 years of age or older.
  • Multiple myeloma diagnosed according to standard IMWG criteria.
  • Patients must have measurable disease defined by at least one of the following three measurements:
  • Serum M-protein 1 g/dL (10 g/L).
  • Urine M-protein 200 mg/24 hours.
Show all 27Show fewer
  • Serum free light chain assay: involved free light chain level at least 100 mg/L, provided that the serum free light chain ratio is abnormal.
  • Patients received one or two prior lines of therapy which must have included bortezomib, lenalidomide-and daratumumab.
  • Patient received carfilzomib-based therapy either as their most recent line of therapy and within 3 months from study enrolment, and either failed to achieve a minor response after completing 2 cycles of carfilzomib based therapy, or are refractory to treatment.
  • Patients were found to have a high-expression level of PPIA, >1.2 unique RNA molecules (UMI) per cell on average, by scRNA sequencing of their myeloma cells from bone marrow aspiration sample at study screening.
  • Patients must meet the following clinical laboratory criteria:
  • Absolute neutrophil count (ANC) ≥1,000/mm3 and platelet count≥75,000/mm3. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days of enrolment.
  • Total bilirubin ≤1.5 the upper limit of the normal range (ULN).
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 ULN.
  • Calculated creatinine clearance ≥45 mL/min
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
  • Female patients who:
  • Are postmenopausal for at least 24 months before the screening visit, OR
  • Are surgically sterile, OR
  • Who are of childbearing potential, and agree to practice two effective methods of contraception (1 highly effective method and 1 additional effective method) at the same time, from the time of signing the informed consent through 90 days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse.
  • Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 milli International Units/mL within 10 to 14 days of initiation of Cycle 1 and again within 24 hours of starting Cycle 1. FCBP must also agree to ongoing pregnancy testing. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
  • Male patients, even if surgically sterilized (i.e., status postvasectomy), who:
  • Agree to completely abstain from heterosexual intercourse, OR
  • Agree to practice effective barrier contraception (i.e., latex condom) during sexual contact with a FCBP, even if they have had a successful vasectomy, throughout the entire study treatment period and through 4 months after the last dose of study treatment.
  • Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
  • Patient is willing and able to adhere to the study visit schedule and other protocol requirements.
  • -

Who cannot join

  • Patients meeting any of the following exclusion criteria are not eligible to participate in the study:
  • Patient underwent an allogeneic transplantation.
  • Major surgery within 14 days before enrolment.
  • Central nervous system involvement
  • Concomitant use of any other antineoplastic treatment with activity against MM (with the exception of ≤40 mg Dexamethasone per day or equivalent for no longer than 4 days).
  • Anti-myeloma therapy as follows prior to screening bone marrow aspiration:
Show all 31Show fewer
  • Targeted therapy, within 14 days or at least 5 half-lives, whichever is less;
  • Monoclonal antibody treatment for multiple myeloma within 21 days;
  • Cytotoxic therapy within 14 days;
  • Proteasome inhibitor therapy within 14 days; note: no window is required for carfilzomib
  • Immunomodulatory agent therapy within 7 days.
  • Radiotherapy within 14 days (with the exception of radiotherapy for spinal cord compression or for pain control that should be discussed and approved by the sponsor- investigator prior to study enrolment). However, if the radiation portal covered ≤5% of the bone marrow reserve, the subject is eligible irrespective of the end date of radiotherapy.
  • Diagnosed or treated for another malignancy within 2 years before enrolment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  • Moderate to severe kidney injury (Calculated creatinine clearance ≤45 mL/min).
  • Severe liver disease (cirrhosis grade Child-Pugh B or C; significant hepatocellular or cholestatic liver injury).
  • Diagnosis of Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome, plasma cell leukaemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome.
  • Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
  • Psychiatric illness/social situation that would limit compliance with study requirements.
  • Patient with a known diagnosis of Epilepsy.
  • Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
  • Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Systemic treatment with strong inhibitors of Cytochrome P450 family 3, subfamily A (CYP3A) (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong Cytochrome P450 (CYP3A), family 3, subfamily A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within 14 days before enrolment in the study.
  • Infection requiring systemic antibiotic therapy or other serious infection within 14 days before enrolment.
  • Ongoing or active systemic infection, active hepatitis B virus infection, active hepatitis C infection, or known human immunodeficiency virus (HIV) positive.
  • Vaccination with live attenuated viruses (i.e. yellow fever injections, polio drops, chickenpox (herpes varicella) and shingles (herpes zoster) vaccines) within 30 days before enrolment.
  • Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or known GI disease or planned gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.
  • Failure to have fully recovered (ie, Grade 1 toxicity) from the reversible effects of prior chemotherapy (except for alopecia).
  • Patient has Grade 3 peripheral neuropathy during the screening period.
  • Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial.
  • Patients that have previously been treated with Cyclosporine plus carfilzomib.
  • Female patients who are lactating or pregnant.

Trial locations and contacts

1 site in 1 country.

Israel1 site

  • Tel Aviv Sourasky Medical Center

    Tel Aviv

Other trials in Israel

About this study

Official title: A Single-arm, Prospective Study of Cyclosporine in Combination With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma Refractory to Carfilzomib With High Expression of the Peptidylprolyl Isomerase A (PPIA) Gene in Myeloma Cells

This phase 1, open-label, single-arm, prospective, single center study will evaluate the safety, tolerability and efficacy of cyclosporine in combination with carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma (RRMM).

Read the detailed description

This phase 1, open-label, single-arm, prospective, single center study will evaluate the safety, tolerability and efficacy of cyclosporine in combination with carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma (RRMM). The patients will consist of adult men and women who have a confirmed diagnosis of RRMM, who have received at least two prior lines of therapy including carfilzomib, and were non responsive or refractory to carfilzomib as specified below, and who were found to have elevated expression of Peptidylprolyl Isomerase A (PPIA) in scRNA sequencing of their myeloma cells, and who meet other protocol outlined eligibility criteria.

The patients will be treated with cyclosporine with dose titration based on repeated determinations of whole blood concentrations to achieve a target trough concentration of 250 ng/mL, in combination with carfilzomib plus dexamethasone.

Patients may continue to receive treatment for 4 months or until disease progression or unacceptable toxicity, the earliest of them.

Subjects will be followed for Adverse Events (AEs), clinical status-Overall response rate (ORR) as defined by International Myeloma Working Group (IMWG) criteria, Progression Free Survival (PFS), Duration of Response (DOR), Time to Progression (TTP), stringent Complete Response (sCR 0, Complete Response (CR), Very Goog Partial Response (VGPR), Partial Response (PR), Depth of Best Response (DpR), Time To Response (TTR), Progressive Disease (PD), Overall Survival (OS) and laboratory parameters for up to 4 months, unless they terminate early due to disease progression, unacceptable toxicity or due to meeting one of the withdrawal criteria

Being tested
cyclosporine in combination with carfilzomib and dexamethasone
Medical subject headings
Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • cyclosporine in combination with carfilzomib and dexamethasoneDrug

    patients will be treated with cyclosporine with dose titration based on repeated determinations of whole blood concentrations to achieve a target trough concentration of 250 ng/mL, in combination with carfilzomib plus dexamethasone.

Study groups in NCT04813653
Study groupRoleWhat they receive
cyclosporine in combination with carfilzomib and dexamethasoneExperimentalcyclosporine in combination with carfilzomib and dexamethasone in patients with relapsed multiple myeloma refractory to carfilzomib with high expression of the PPIA gene in myeloma cells
Receives: Drug: cyclosporine in combination with carfilzomib and dexamethasone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.

    Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.

    Measured: follow-up 2 years post study

Secondary outcomes (11)

  1. Overall response rate ORR

    Proportion of patients who achieve a best overall response of stringent complete response , complete response, very good partial response, or partial response as defined using the IMWG criteria

    Measured: follow-up 2 years post study

  2. Progression free survival PFS

    The time from first dose to the date of the first documented tumor progression or death due to any cause. PFS will be determined by an investigator, based upon laboratory data, as defined by the IMWG criteria

    Measured: follow-up 2 years post study

  3. Duration of Response DOR

    The time between the date of first response to the date of the first objectively documented tumor progression as assessed by study steering committee according to modified IMWG criteria or death due to any cause prior to subsequent anti-cancer therapy.

    Measured: follow-up 2 years post study

  4. Time to Response TTR

    The time from the first dose to the date of the first sCR, CR, VGPR, or PR.

    Measured: follow-up 2 years post study

  5. Depth of Best Response (DpR)

    According to IMWG criteria.

    Measured: follow-up 2 years post study

  6. Time to progression (TTP)

    Time from initiation of treatment to documented PD

    Measured: follow-up 2 years post study

  7. Overall Survival (OS)

    Time between the date of first dose and the date of death due to any cause

    Measured: follow-up 2 years post study

  8. Extramedullary progression

    Kaplan Meyer test will be applied to test for differences between the groups in Progression Free Survival

    Measured: follow-up 2 years post study

  9. Extramedullary progression

    Kaplan Meyer test will be applied to test for differences between the groups in Overall Survival

    Measured: follow-up 2 years post study

  10. Percentage of cyclosporine trough levels tests in acceptable range

    will be calculated for each patient.

    Measured: follow-up 2 years post study

  11. Mean % of levels in acceptable range will be calculated for the efficacy population.

    Measured: follow-up 2 years post study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Mar 2021
  2. Study start18 Apr 2021
  3. Primary completion5 Mar 2025
  4. Study completion5 Mar 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
single-arm, prospective study
Masking
None (open label)
Enrolment
3 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04813653
Sponsor's protocol ID
1007-20-TLV
Status last verified
Aug 2024
First submitted
18 Mar 2021
Last updated
24 Jul 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing cyclosporine in combination with carfilzomib and dexamethasone in people with Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 27 inclusion and 31 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters. (time frame: follow-up 2 years post study). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04813653.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in